Prophylactic Cefazolin Dosing in Obesity-a Systematic Review.

Area of Science:

• Surgical prophylaxis
• Pharmacokinetics
• Obesity medicine

Background:

• Obesity presents unique challenges in achieving adequate drug concentrations for surgical site infection prevention.
• The standard 2-g cefazolin dose is commonly used, but its efficacy in obese patients is debated.

Purpose of the Study:

• To systematically review existing evidence on the adequacy of standard 2-g cefazolin prophylaxis in obese surgical patients.
• To determine optimal cefazolin dosing strategies for this population.

Main Methods:

• A systematic literature search was performed across four databases.
• Included studies comprised both clinical outcomes and pharmacokinetic analyses relevant to cefazolin dosing in obesity.

Main Results:

• Three outcome studies indicated no need for dose escalation.
• Fifteen pharmacokinetic studies yielded mixed results: 9 supported the standard dose, while 6 suggested it may be insufficient.
• A stronger evidence base supports the 2-g dose for surgeries up to 4 hours.

Conclusions:

• The current evidence suggests that a 2-g cefazolin dose is likely adequate for surgical prophylaxis in obese patients for procedures up to 4 hours.
• Further large-scale outcome studies are necessary to definitively confirm these findings and establish definitive dosing guidelines.